- Home
- MLYS vs MEGI Comparison
MLYS vs MEGI Comparison
Compare MLYS & MEGI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MLYS
- MEGI
- Stock Information
- Founded
- MLYS 2019
- MEGI 2021
- Country
- MLYS United States
- MEGI United States
- Employees
- MLYS N/A
- MEGI N/A
- Industry
- MLYS Biotechnology: Pharmaceutical Preparations
- MEGI Investment Managers
- Sector
- MLYS Health Care
- MEGI Finance
- Exchange
- MLYS Nasdaq
- MEGI Nasdaq
- Market Cap
- MLYS 890.6M
- MEGI 749.0M
- IPO Year
- MLYS 2023
- MEGI N/A
- Fundamental
- Price
- MLYS $14.89
- MEGI $14.43
- Analyst Decision
- MLYS Strong Buy
- MEGI
- Analyst Count
- MLYS 4
- MEGI 0
- Target Price
- MLYS $27.00
- MEGI N/A
- AVG Volume (30 Days)
- MLYS 869.6K
- MEGI 178.0K
- Earning Date
- MLYS 08-12-2025
- MEGI 01-01-0001
- Dividend Yield
- MLYS N/A
- MEGI 11.40%
- EPS Growth
- MLYS N/A
- MEGI N/A
- EPS
- MLYS N/A
- MEGI N/A
- Revenue
- MLYS N/A
- MEGI N/A
- Revenue This Year
- MLYS N/A
- MEGI N/A
- Revenue Next Year
- MLYS N/A
- MEGI N/A
- P/E Ratio
- MLYS N/A
- MEGI N/A
- Revenue Growth
- MLYS N/A
- MEGI N/A
- 52 Week Low
- MLYS $8.24
- MEGI $10.63
- 52 Week High
- MLYS $18.38
- MEGI $14.89
- Technical
- Relative Strength Index (RSI)
- MLYS 55.68
- MEGI 54.89
- Support Level
- MLYS $14.26
- MEGI $14.26
- Resistance Level
- MLYS $15.55
- MEGI $14.50
- Average True Range (ATR)
- MLYS 0.85
- MEGI 0.13
- MACD
- MLYS 0.18
- MEGI -0.01
- Stochastic Oscillator
- MLYS 77.53
- MEGI 62.12
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.
About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund
NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.